149 related articles for article (PubMed ID: 38097739)
1. Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer.
Zebic DS; Tjokrowidjaja A; Francis KE; Friedlander M; Gebski V; Lortholary A; Joly F; Hasenburg A; Mirza M; Denison U; Cecere SC; Ferrero A; Pujade-Lauraine E; Lee CK
Br J Cancer; 2024 Feb; 130(3):425-433. PubMed ID: 38097739
[TBL] [Abstract][Full Text] [Related]
2. Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
Tjokrowidjaja A; Friedlander ML; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Lord SJ; Scott CL; Goble S; York W; Lee CK;
J Clin Oncol; 2024 Apr; 42(11):1301-1310. PubMed ID: 38215359
[TBL] [Abstract][Full Text] [Related]
3. Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
Lindemann K; Kristensen G; Mirza MR; Davies L; Hilpert F; Romero I; Ayhan A; Burges A; Rubio MJ; Raspagliesi F; Huizing M; Creemers GJ; Lykka M; Lee CK; Gebski V; Pujade-Lauraine E
Ann Oncol; 2016 Aug; 27(8):1505-10. PubMed ID: 27407100
[TBL] [Abstract][Full Text] [Related]
4. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
[TBL] [Abstract][Full Text] [Related]
5. Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
Tjokrowidjaja A; Lee CK; Friedlander M; Gebski V; Gladieff L; Ledermann J; Penson R; Oza A; Korach J; Huzarski T; Manso L; Pisano C; Asher R; Lord SJ; Kim SI; Lee JY; Colombo N; Park-Simon TW; Fujiwara K; Sonke G; Vergote I; Kim JW; Pujade-Lauraine E
Eur J Cancer; 2020 Nov; 139():59-67. PubMed ID: 32977221
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial.
Randall LM; Sill MW; Burger RA; Monk BJ; Buening B; Sorosky JI
Gynecol Oncol; 2012 Mar; 124(3):563-8. PubMed ID: 22138229
[TBL] [Abstract][Full Text] [Related]
7. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.
Alexandre J; Brown C; Coeffic D; Raban N; Pfisterer J; Mäenpää J; Chalchal H; Fitzharris B; Volgger B; Vergote I; Pisano C; Ferrero A; Pujade-Lauraine E
Br J Cancer; 2012 Feb; 106(4):633-7. PubMed ID: 22240800
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.
Ferrandina G; Ludovisi M; Corrado G; Carone V; Petrillo M; Scambia G
Gynecol Oncol; 2008 May; 109(2):187-93. PubMed ID: 18343487
[TBL] [Abstract][Full Text] [Related]
9. Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Bonaventura A; OʼConnell RL; Mapagu C; Beale PJ; McNally OM; Mileshkin LR; Grant PT; Hadley AM; Goh JCH; Sjoquist KM; Martyn J; DeFazio A; Scurry J; Friedlander ML;
Int J Gynecol Cancer; 2017 Jun; 27(5):900-906. PubMed ID: 28498256
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
Trédan O; Provansal M; Abdeddaim C; Lardy-Cleaud A; Hardy-Bessard AC; Kalbacher E; Floquet A; Venat-Bouvet L; Lortholary A; Pop O; Frenel JS; Cancel M; Largillier R; Louvet C; You B; Zannetti A; Anota A; Treilleux I; Pissaloux D; Houlier A; Savoye AM; Mouret-Reynier MA; Meunier J; Levaché CB; Brocard F; Ray-Coquard I
Gynecol Oncol; 2022 Jan; 164(1):18-26. PubMed ID: 34696892
[TBL] [Abstract][Full Text] [Related]
11. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).
You B; Colomban O; Heywood M; Lee C; Davy M; Reed N; Pignata S; Varsellona N; Emons G; Rehman K; Steffensen KD; Reinthaller A; Pujade-Lauraine E; Oza A
Gynecol Oncol; 2013 Aug; 130(2):289-94. PubMed ID: 23694718
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Frenel JS; Kim JW; Aryal N; Asher R; Berton D; Vidal L; Pautier P; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Colombo N; Park-Simon TW; Tamura K; Sonke GS; Freimund AE; Lee CK; Pujade-Lauraine E
Ann Oncol; 2022 Oct; 33(10):1021-1028. PubMed ID: 35772665
[TBL] [Abstract][Full Text] [Related]
13. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
14. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
[TBL] [Abstract][Full Text] [Related]
15. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?
Gronlund B; Høgdall C; Hilden J; Engelholm SA; Høgdall EV; Hansen HH
J Clin Oncol; 2004 Oct; 22(20):4051-8. PubMed ID: 15364966
[TBL] [Abstract][Full Text] [Related]
16. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
Cadron I; Leunen K; Amant F; Van Gorp T; Neven P; Vergote I
Gynecol Oncol; 2007 Aug; 106(2):354-61. PubMed ID: 17499348
[TBL] [Abstract][Full Text] [Related]
17. Oral cyclophosphamide in recurrent ovarian cancer.
Handolias D; Quinn M; Foo S; Mileshkin L; Grant P; Dutu G; Rischin D
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e154-60. PubMed ID: 23718870
[TBL] [Abstract][Full Text] [Related]
18. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).
Rustin GJ; Vergote I; Eisenhauer E; Pujade-Lauraine E; Quinn M; Thigpen T; du Bois A; Kristensen G; Jakobsen A; Sagae S; Greven K; Parmar M; Friedlander M; Cervantes A; Vermorken J;
Int J Gynecol Cancer; 2011 Feb; 21(2):419-23. PubMed ID: 21270624
[TBL] [Abstract][Full Text] [Related]
19. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Shah PD; Wethington SL; Pagan C; Latif N; Tanyi J; Martin LP; Morgan M; Burger RA; Haggerty A; Zarrin H; Rodriguez D; Domchek S; Drapkin R; Shih IM; Smith SA; Dean E; Gaillard S; Armstrong D; Torigian DA; Hwang WT; Giuntoli R; Simpkins F
Gynecol Oncol; 2021 Nov; 163(2):246-253. PubMed ID: 34620496
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
Selle F; Sevin E; Ray-Coquard I; Mari V; Berton-Rigaud D; Favier L; Fabbro M; Lesoin A; Lortholary A; Pujade-Lauraine E
Ann Oncol; 2014 Nov; 25(11):2191-2196. PubMed ID: 25210017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
